Specific elevation of DcR3 in sera of sepsis patients and its potential role as a clinically important biomarker of sepsis

Diagnostic Microbiology and Infectious Disease

Volumn 73, Issue 4, 2012, Pages 312-317

  Kim, Sunghee ^a   Mi, Lijun ^b   Zhang, Lurong ^b  

^a BioPowerTech   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Apoptosis; Biomarker; DcR3; Immunomodulation; Inflammation; Sepsis

Indexed keywords

BIOLOGICAL MARKER; DECOY RECEPTOR 3; OSTEOPROTEGERIN; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR LIKE LIGAND 1; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CROHN DISEASE; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FUNGEMIA; GRAM NEGATIVE SEPSIS; GRAM POSITIVE INFECTION; HUMAN; KIDNEY CARCINOMA; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RELIABILITY; SENSITIVITY AND SPECIFICITY; SEPSIS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; UPREGULATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MIDDLE AGED; OSTEOPROTEGERIN; RECEPTORS, TUMOR NECROSIS FACTOR, MEMBER 6B; ROC CURVE; SENSITIVITY AND SPECIFICITY; SEPSIS; TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 15; YOUNG ADULT;

EID: 84863781797     PISSN: 07328893     EISSN: 18790070     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2012.04.008     Document Type: Article

References (33)

1. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992, 20:864-874.
2. Angus D.C., Linde-Zwirble W.T., Lidicker J., Clermont G., Carcillo J., Pinsky M.R. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001, 29:1303-1310.
3. Boomer J.S., To K., Chang K.C., Takasu O., Osborne D.F., Walton A.H., et al. Immunosuppression in patients who die of sepsis and multiple organ failure. JAMA 2011, 306:2594-2605.
4. Calich V.L., Pina A., Felonato M., Bernardino S., Costa T.A., Loures F.V. Toll-like receptors and fungal infections: the role of TLR2, TLR4 and MyD88 in paracoccidioidomycosis. FEMS Immunol Med Microbiol 2008, 53:1-7.
5. Chang Y.C., Hsu T.L., Lin H.H., Chio C.C., Chiu A.W., Chen N.J., et al. Modulation of macrophage differentiation and activation by decoy receptor 3. J Leukoc Biol 2004, 75:486-494.
6. Chen J., Zhang L., Kim S. Quantification and detection of DcR3, a decoy receptor in TNFR family. J Immunol Methods 2004, 285:63-70.
7. Chen C.Y., Yang K.Y., Chen M.Y., Chen H.Y., Lin M.T., Lee Y.C., et al. Decoy receptor 3 levels in peripheral blood predict outcomes of acute respiratory distress syndrome. Am J Respir Crit Care Med 2009, 180:751-760.
8. Decker T. Sepsis: avoiding its deadly toll. J Clin Invest 2004, 113:1387-1389.
9. Devitt A., Marshall L.J. The innate immune system and the clearance of apoptotic cells. J Leukoc Biol 2011, 90:447-457.
10. Faherty C.S., Maurelli A.T. Staying alive: bacterial inhibition of apoptosis during infection. Trends Microbiol 2008, 16:173-180.
11. Funke B., Autschbach F., Kim S., Lasitschka F., Strauch U., Rogler G., et al. Functional characterisation of decoy receptor 3 in Crohn's disease. Gut 2009, 58:483-491.
12. Hayashi S., Miura Y., Tateishi K., Takahashi M., Kurosaka M. Decoy receptor 3 is highly expressed in patients with rheumatoid arthritis. Mod Rheumatol 2010, 20:63-68.
13. Hsu T.L., Chang Y.C., Chen S.J., Liu Y.J., Chiu A.W., Chio C.C., et al. Modulation of dendritic cell differentiation and maturation by decoy receptor 3. J Immunol 2002, 168:4846-4853.
14. Hsu T.L., Wu Y.Y., Chang Y.C., Yang C.Y., Lai M.Z., Su W.B., et al. Attenuation of Th1 response in decoy receptor 3 transgenic mice. J Immunol 2005, 175:5135-5145.
15. Karlsson S., Heikkinen M., Pettilä V., Alila S., Väisänen S., Pulkki K., et al. Predictive value of procalcitonin decrease in patients with severe sepsis: a prospective observational study. Crit Care 2010, 14:R205.
16. Kim S., Zhang L. Identification of naturally secreted soluble form of TL1A, a TNF-like cytokine. J Immunol Methods 2005, 298:1-8.
17. Kim S., McAuliffe W.J., Zaritskaya L.S., Moore P.A., Zhang L., Nardelli B. Selective induction of tumor necrosis receptor factor 6/decoy receptor 3 release by bacterial antigens in human monocytes and myeloid dendritic cells. Infect Immun 2004, 72:89-93.
18. Kim S., Fotiadu A., Kotoula V. Increased expression of soluble decoy receptor 3 in acutely inflamed intestinal epithelia. Clin Immunol 2005, 115:286-294.
19. Kim S., Kotoula V., Hytiroglou P., Zardavas D., Zhang L. Significance of increased expression of decoy receptor 3 in chronic liver disease. Dig Liver Dis 2009, 41:591-598.
20. Klouche M., Schröder U. Rapid methods for diagnosis of bloodstream infections. Clin Chem Lab Med 2008, 46:888-908.
21. Lyn-Kew K., Standiford T.J. Immunosuppression in sepsis. Curr Pharm Des 2008, 14:1870-1881.
22. Macher-Goeppinger S., Aulmann S., Wagener N., Funke B., Tagscherer K.E., Haferkamp A., et al. Decoy receptor 3 is a prognostic factor in renal cell cancer. Neoplasia 2008, 10:1049-1056.
23. Migone T.S., Zhang J., Luo X., Zhuang L., Chen C., Hu B., et al. TL1A is a TNF-like ligand for DR3 and TR6/DcR3 and functions as a T cell costimulator. Immunity 2002, 16:479-492.
24. Oddo M., Renno T., Attinger A., Bakker T., MacDonald H.R., Meylan P.R. Fas ligand-induced apoptosis of infected human macrophages reduces the viability of intracellular Mycobacterium tuberculosis. J Immunol 1998, 160:5448-5454.
25. Pierrakos C., Vincent J.L. Sepsis biomarkers: a review. Crit Care 2010, 14:R15.
26. Pitti R.M., Marsters S.A., Lawrence D.A., Roy M., Kischkel F.C., Dowd P., et al. Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature 1998, 396:699-703.
27. Shubin N.J., Monaghan S.F., Ayala A. Anti-inflammatory mechanisms of sepsis. Contrib Microbiol 2011, 17:108-124.
28. So L.K., Lau A.C., Yam L.Y., Cheung T.M., Poon E., Yung R.W., et al. Development of a standard treatment protocol for severe acute respiratory syndrome. Lancet 2003, 361:1615-1617.
29. Takahama Y., Yamada Y., Emoto K., Fujimoto H., Takayama T., Ueno M., et al. The prognostic significance of overexpression of the decoy receptor for Fas ligand (DcR3) in patients with gastric carcinomas. Gastric Cancer 2002, 5:61-68.
30. Tu H.F., Liu C.J., Liu S.Y., Chen Y.P., Yu E.H., Lin S.C., et al. Serum decoy receptor 3 level: a predictive marker for nodal metastasis and survival among oral cavity cancer patients. Head Neck 2011, 33:396-402.
31. You R.I., Chang Y.C., Chen P.M., Wang W.S., Hsu T.L., Yang C.Y., et al. Apoptosis of dendritic cells induced by decoy receptor 3 (DcR3). Blood 2008, 111:1480-1488.
32. Yu K.Y., Kwon B., Ni J., Zhai Y., Ebner R., Kwon B.S. A newly identified member of tumor necrosis factor receptor superfamily (TR6) suppresses LIGHT-mediated apoptosis. J Biol Chem 1999, 274:13733-13736.
33. Zhai Y., Guo R., Hsu T.L., Yu G.L., Ni J., Kwon B.S., et al. LIGHT, a novel ligand for lymphotoxin beta receptor and TR2/HVEM induces apoptosis and suppresses in vivo tumor formation via gene transfer. J Clin Invest 1998, 102:1142-1151.